All In Biotech

Drug Trial Radar · NCT06809322

Vorasidenib Maintenance for IDH Mutant Astrocytoma

Vorasidenib as Maintenance Treatment After First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma: a Placebo-controlled, Triple-blind, Randomized Phase III Study (VIGOR)

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 468 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

468

Planned (sponsor's estimate)

Start

Jan 16, 2026

Primary completion

Apr 13, 2035

Study completion May 31, 2037

Sponsor

Sponsor type
Research network
Collaborators
Canadian Cancer Trials Group; Olivia Newton-John Cancer Research Institute
First posted
Feb 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free survival (PFS) from enrolment compared to placebo in patients with IDH-mutant, CNS5 WHO Grade 2 or 3 astrocytoma following the completion of first-line chemoradiotherapy. The primary endpoint is Progression-free survival (PFS), as assessed locally from the date of enrolment using the RANO 2.0 criteria. In this a comparative, randomized (1:1), triple blinded, multicentre phase III superiority trial with one stopping rule for efficacy and futility after end of enrolment, participants in the experimental arm will receive vorasidenib orally once daily at a dose of 40 mg in continuous 28-day cycles while participants in the control arm will receive a matched oral placebo once daily in continuous 28-day cycles

Conditions

  • IDH-mutant Grade 2 or 3 Astrocytoma

Interventions

  • VorasidenibDrug

    Vorasidinib will be administered orally once daily at a dose of 40 mg in continuous 28-day cycles

  • Vorasidenib PlaceboDrug

    Matched oral vorasidenib placebo will be administered once daily in continuous 28-day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) by local assessmentTime frame: ~7.7 years and 10.5 years from first patient in

Locations

59 sites in 12 countries. Site status is shown where the registry gives one.

  • Flinders Medical Centre / Southern Adelaide Local Health Network

    Bedford Park, Australia · Not yet recruiting

  • Chris O'Brien LifeHouse

    Camperdown, Australia · Not yet recruiting

  • Austin Hospital

    Heidelberg, Australia · Not yet recruiting

  • Royal Hobart Hospital

    Hobart, Australia · Not yet recruiting

  • Liverpool Hospital

    Liverpool, Australia · Not yet recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Not yet recruiting

  • the Alfred hospital

    Melbourne, Australia · Not yet recruiting

  • Sir Charles Gairdner Hospital

    Nedlands, Australia · Not yet recruiting

  • Royal North Shore Hospital

    St Leonards, Australia · Not yet recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Australia · Recruiting

  • Medical University of Innsbruck

    Innsbruck, Austria · Recruiting

  • Kepler University Hospital - Neuromed campus

    Linz, Austria · Recruiting

  • Medical University of Vienna

    Vienna, Austria · Recruiting

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium · Recruiting

  • Ghent University Hospital

    Ghent, Belgium · Recruiting

  • U.Z. Leuven - Campus Gasthuisberg

    Leuven, Belgium · Recruiting

  • Arthur J.E. Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada · Not yet recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Not yet recruiting

  • BC Cancer Agency - Vancouver

    Vancouver, British Columbia, Canada · Not yet recruiting

  • CancerCare Manitoba

    Winnipeg, Manitoba, Canada · Recruiting

  • QEII Health Sciences Centre Capital District Health Authority

    Halifax, Nova Scotia, Canada · Not yet recruiting

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada · Not yet recruiting

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada · Not yet recruiting

  • London Health Sciences Centre Research Inc.

    London, Ontario, Canada · Not yet recruiting

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada · Not yet recruiting

  • Odette Cancer Centre Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada · Recruiting

  • University Health Network Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • CHUM-Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, Canada · Not yet recruiting

  • Montreal Neurological Institute and Hospital James Administration Building

    Montreal, Quebec, Canada · Not yet recruiting

  • CIUSSS NIM - Hôpital du Sacré-Cœur de Montréal

    Montreal, Quebec, Canada · Not yet recruiting

  • Hotel-Dieu de Quebec

    Québec, Quebec, Canada · Not yet recruiting

  • CIUSSS de l'Estrie - Centre hospitalier universitaire de Sherbrooke

    Sherbrooke, Quebec, Canada · Not yet recruiting

  • Masaryk Memorial Cancer Institute

    Brno, Czechia · Recruiting

  • Universitary hospital Bordeaux France

    Bordeaux, France · Recruiting

  • CHU Lyon - Hopital neurologique Pierre Wertheimer

    Lyon, France · Recruiting

  • Marseille APHM

    Marseille, France · Recruiting

  • Assistance Publique Hopitaux de Paris APHP - Sorbonne

    Paris, France · Recruiting

  • Oncopole Claudius Regaud, IUCT-Oncopole

    Toulouse, France · Recruiting

  • Universitaskliniken Bonn

    Bonn, Germany · Recruiting

  • University Hospital Frankfurt -Senckenberg Institute of Neurooncology

    Frankfurt, Germany · Recruiting

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.